Tag Archives: Status

Quadient Secures Supplier Status on NHS Shared Business Services Framework Agreement

Quadient included on three Lots for patient/citizen communications and engagement solutions London, 10 January, 2022 Quadient UK, a leader in helping businesses create meaningful customer connections through digital and physical channels, has been named as a supplier on three Lots of the NHS Shared Business Services (NHS SBS) Patient/Citizen Communications and Engagement Solutions Framework. NHS… Read More »

Zambian study finds no link between HIV status and COVID-19 severity, but risk quadruples for people with severe HIV infection

Having HIV is not an independent risk factor for severe COVID-19 and death amongst patients hospitalised with COVID-19, according to a Zambian study published in the Morbidity and Mortality Weekly Report. However, patients with more severe HIV infection are more likely to develop severe COVID-19 or die of COVID-19 compared to those without complications. “This… Read More »

HIV status does not affect immune responses to Oxford/AstraZeneca vaccine, two studies show

Two studies of immune responses to the Oxford/AstraZeneca COVID-19 vaccine show that the vaccine produced similar immune responses in people with or without HIV. People with HIV did not experience more side effects from the vaccine. The findings have been made available as pre-prints, which means that they have not been peer-reviewed yet. There is… Read More »

Logicalis Renews Microsoft Azure Expert Managed Service Provider Status

London – 10th February 2021 – Logicalis Group, an international IT solutions and managed services provider, has today announced its renewed status as a Microsoft Azure Expert Managed Services Provider (MSP). The Azure Expert MSP program is a global initiative from Microsoft to highlight and promote partners with the highest level of expertise as managed… Read More »

FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer Regardless of Biomarker Status

Print this page London UK — 29 April 2020 — Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend… Read More »